OGEN - Oragenics: 2 New Phase 1 Trials Should Resurrect Investor Sentiment Driving Upside By 2022
- Oragenics, Inc. is a small development-stage biotechnology company developing novel therapeutics/antibiotics for infectious diseases, particularly COVID-19 and C. difficile.
- Oragenics is developing two pre-IND candidates for infectious diseases which aim to both submit INDs in 4Q 2021 with their lead candidate as Terra CoV-2, a differentiated pre-fusion targeting vaccine.
- Oragenics is in a normal financial position with cash at 1Q 2021 of $36.5M, no revenues expected before 2024, and an expected cash burn of ~$28M outlining funding through 2Q22.
- Oragenics' next major catalyst will be the Phase 1 initiation of the COVID-19 vaccine candidate, Terra CoV-2, in 4Q 2021.
- In summary, the author projects Oragenics, Inc. as a "buy" at a 2-3 year price target of $2.00 (+203% upside).
For further details see:
Oragenics: 2 New Phase 1 Trials Should Resurrect Investor Sentiment, Driving Upside By 2022